All these results indicated that blocking ANGPTL3 was a novel therapeutic approaches for NAFLD with satisfactory efficacy and safety (in Additional file 1: Fig. S5). Here, ANGPTL3 is linked to metabolic dysfunction-associated steatotic liver disease.